Blueprint Medicines Corporation (0HOJ.L)
USD 85.0
(-2.48%)
USD 85.0
(-2.48%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 1.04 Billion USD | -22.27% |
| 2022 | 1.34 Billion USD | 7.8% |
| 2021 | 1.25 Billion USD | -27.13% |
| 2020 | 1.71 Billion USD | 142.82% |
| 2019 | 707.69 Million USD | 31.02% |
| 2018 | 540.12 Million USD | -24.54% |
| 2017 | 715.73 Million USD | 153.09% |
| 2016 | 282.79 Million USD | 58.08% |
| 2015 | 178.89 Million USD | 258.33% |
| 2014 | 49.92 Million USD | 1107.38% |
| 2013 | 4.13 Million USD | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 1.19 Billion USD | -0.32% |
| 2024 Q1 | 1.03 Billion USD | -1.03% |
| 2024 Q2 | 1.2 Billion USD | 15.9% |
| 2023 Q4 | 1.04 Billion USD | -5.07% |
| 2023 Q1 | 1.22 Billion USD | -9.6% |
| 2023 FY | 1.04 Billion USD | -22.27% |
| 2023 Q2 | 1.1 Billion USD | -9.34% |
| 2023 Q3 | 1.1 Billion USD | -0.1% |
| 2022 FY | 1.34 Billion USD | 7.8% |
| 2022 Q4 | 1.34 Billion USD | -7.44% |
| 2022 Q3 | 1.45 Billion USD | 22.3% |
| 2022 Q2 | 1.19 Billion USD | 4.3% |
| 2022 Q1 | 1.14 Billion USD | -8.7% |
| 2021 FY | 1.25 Billion USD | -27.13% |
| 2021 Q3 | 1.47 Billion USD | -5.83% |
| 2021 Q4 | 1.25 Billion USD | -15.24% |
| 2021 Q1 | 1.62 Billion USD | -5.41% |
| 2021 Q2 | 1.56 Billion USD | -3.48% |
| 2020 Q2 | 817.45 Million USD | -10.53% |
| 2020 Q3 | 1.55 Billion USD | 90.61% |
| 2020 FY | 1.71 Billion USD | 142.82% |
| 2020 Q4 | 1.71 Billion USD | 10.28% |
| 2020 Q1 | 913.62 Million USD | 29.1% |
| 2019 Q3 | 737.92 Million USD | -8.58% |
| 2019 Q1 | 544.66 Million USD | 0.84% |
| 2019 Q4 | 707.69 Million USD | -4.1% |
| 2019 Q2 | 807.17 Million USD | 48.2% |
| 2019 FY | 707.69 Million USD | 31.02% |
| 2018 Q1 | 664.46 Million USD | -7.16% |
| 2018 FY | 540.12 Million USD | -24.54% |
| 2018 Q2 | 665.11 Million USD | 0.1% |
| 2018 Q3 | 606.11 Million USD | -8.87% |
| 2018 Q4 | 540.12 Million USD | -10.89% |
| 2017 Q3 | 420.11 Million USD | -5.53% |
| 2017 Q2 | 444.72 Million USD | 76.02% |
| 2017 Q4 | 715.73 Million USD | 70.37% |
| 2017 FY | 715.73 Million USD | 153.09% |
| 2017 Q1 | 252.64 Million USD | -10.66% |
| 2016 Q3 | 167.84 Million USD | -10.01% |
| 2016 FY | 282.79 Million USD | 58.08% |
| 2016 Q4 | 282.79 Million USD | 68.48% |
| 2016 Q2 | 186.52 Million USD | -9.46% |
| 2016 Q1 | 206.01 Million USD | 15.16% |
| 2015 Q1 | 55.91 Million USD | 11.99% |
| 2015 FY | 178.89 Million USD | 258.33% |
| 2015 Q2 | 204.2 Million USD | 265.24% |
| 2015 Q3 | 195.28 Million USD | -4.37% |
| 2015 Q4 | 178.89 Million USD | -8.39% |
| 2014 Q1 | - USD | 0.0% |
| 2014 Q4 | 49.92 Million USD | 0.0% |
| 2014 FY | 49.92 Million USD | 1107.38% |
| 2013 FY | 4.13 Million USD | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| uniQure N.V. | 831.68 Million USD | -26.159% |
| Agios Pharmaceuticals, Inc. | 937.11 Million USD | -11.966% |
| Amicus Therapeutics, Inc. | 777.88 Million USD | -34.886% |
| Atara Biotherapeutics, Inc. | 165.5 Million USD | -533.973% |
| bluebird bio, Inc. | 619.16 Million USD | -69.463% |
| Cara Therapeutics, Inc. | 125.84 Million USD | -733.77% |
| Imunon, Inc. | 21.91 Million USD | -4687.146% |
| Editas Medicine, Inc. | 499.15 Million USD | -110.206% |
| IQVIA Holdings Inc. | 26.68 Billion USD | 96.067% |
| Mettler-Toledo International Inc. | 3.35 Billion USD | 68.731% |
| Myriad Genetics, Inc. | 1.19 Billion USD | 12.468% |
| Neurocrine Biosciences, Inc. | 3.25 Billion USD | 67.729% |
| Supernus Pharmaceuticals, Inc. | 1.4 Billion USD | 25.531% |
| Verastem, Inc. | 149.71 Million USD | -600.818% |
| Walgreens Boots Alliance, Inc. | 81.03 Billion USD | 98.705% |
| Waters Corporation | 4.62 Billion USD | 77.323% |
| Thermo Fisher Scientific Inc. | 98.72 Billion USD | 98.937% |
| Biogen Inc. | 26.84 Billion USD | 96.091% |
| Nektar Therapeutics | 398.03 Million USD | -163.609% |
| Perrigo Company plc | 10.8 Billion USD | 90.293% |
| Dynavax Technologies Corporation | 997.09 Million USD | -5.231% |
| Illumina, Inc. | 10.11 Billion USD | 89.623% |
| Corbus Pharmaceuticals Holdings, Inc. | 28.27 Million USD | -3611.218% |
| Iovance Biotherapeutics, Inc. | 780.35 Million USD | -34.459% |
| Heron Therapeutics, Inc. | 222.5 Million USD | -371.56% |
| Unity Biotechnology, Inc. | 65.69 Million USD | -1497.275% |
| BioMarin Pharmaceutical Inc. | 6.84 Billion USD | 84.664% |
| Sangamo Therapeutics, Inc. | 165.32 Million USD | -534.678% |
| Evolus, Inc. | 188.99 Million USD | -455.165% |
| Adicet Bio, Inc. | 207.29 Million USD | -406.163% |
| Aclaris Therapeutics, Inc. | 197.4 Million USD | -431.521% |
| Regeneron Pharmaceuticals, Inc. | 33.08 Billion USD | 96.828% |
| Esperion Therapeutics, Inc. | 205.79 Million USD | -409.85% |
| FibroGen, Inc. | 423.52 Million USD | -147.74% |
| Agilent Technologies, Inc. | 10.76 Billion USD | 90.251% |
| OPKO Health, Inc. | 2.01 Billion USD | 47.843% |
| Homology Medicines, Inc. | 47.05 Million USD | -2129.743% |
| Geron Corporation | 394.07 Million USD | -166.256% |
| Alnylam Pharmaceuticals, Inc. | 3.82 Billion USD | 72.604% |
| Exelixis, Inc. | 2.94 Billion USD | 64.34% |
| Viking Therapeutics, Inc. | 368.49 Million USD | -184.743% |
| Anavex Life Sciences Corp. | 154.38 Million USD | -579.628% |
| Intellia Therapeutics, Inc. | 1.3 Billion USD | 19.349% |
| Zoetis Inc. | 14.28 Billion USD | 92.655% |
| Axsome Therapeutics, Inc. | 588.23 Million USD | -78.372% |
| Abeona Therapeutics Inc. | 64 Million USD | -1539.402% |
| Vertex Pharmaceuticals Incorporated | 22.73 Billion USD | 95.384% |
| Kala Pharmaceuticals, Inc. | 55.94 Million USD | -1775.369% |
| Ionis Pharmaceuticals, Inc. | 2.99 Billion USD | 64.909% |
| Sarepta Therapeutics, Inc. | 3.26 Billion USD | 67.86% |
| Corcept Therapeutics Incorporated | 621.51 Million USD | -68.821% |
| Halozyme Therapeutics, Inc. | 1.73 Billion USD | 39.464% |
| Insmed Incorporated | 1.32 Billion USD | 21.099% |
| TG Therapeutics, Inc. | 329.58 Million USD | -218.353% |
| Incyte Corporation | 6.78 Billion USD | 84.529% |
| Emergent BioSolutions Inc. | 1.83 Billion USD | 42.817% |